Division of Boston Scientific Corp.
Latest From IoGyn Inc.
The classification orders touch on surgical, weight loss and cardiac devices and diagnostics.
Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.
Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.
Start-ups raised $893.9 million in Q2 2014, a 25% drop from last quarter’s record-setting $1.18 billion. Metabolic disease was the most prevalent therapeutic category involved in alliances; seven acquisitions were signed, five in the biopharma sector.
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- Boston Scientific Corp.
- Senior Management
- Contact Info
Phone: (408) 252-0101
20195 Stevens Creek Blvd.
Cupertino, CA 95014-2380
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.